167 related articles for article (PubMed ID: 37092555)
1. Tumor loss-of-function mutations in STK11/LKB1 induce cachexia.
Iyengar P; Gandhi AY; Granados J; Guo T; Gupta A; Yu J; Llano EM; Zhang F; Gao A; Kandathil A; Williams D; Gao B; Girard L; Malladi VS; Shelton JM; Evers BM; Hannan R; Ahn C; Minna JD; Infante RE
JCI Insight; 2023 Apr; 8(8):. PubMed ID: 37092555
[TBL] [Abstract][Full Text] [Related]
2. AXL targeting restores PD-1 blockade sensitivity of
Li H; Liu Z; Liu L; Zhang H; Han C; Girard L; Park H; Zhang A; Dong C; Ye J; Rayford A; Peyton M; Li X; Avila K; Cao X; Hu S; Alam MM; Akbay EA; Solis LM; Behrens C; Hernandez-Ruiz S; Lu W; Wistuba I; Heymach JV; Chisamore M; Micklem D; Gabra H; Gausdal G; Lorens JB; Li B; Fu YX; Minna JD; Brekken RA
Cell Rep Med; 2022 Mar; 3(3):100554. PubMed ID: 35492873
[TBL] [Abstract][Full Text] [Related]
3. The AMPK-Related Kinases SIK1 and SIK3 Mediate Key Tumor-Suppressive Effects of LKB1 in NSCLC.
Hollstein PE; Eichner LJ; Brun SN; Kamireddy A; Svensson RU; Vera LI; Ross DS; Rymoff TJ; Hutchins A; Galvez HM; Williams AE; Shokhirev MN; Screaton RA; Berdeaux R; Shaw RJ
Cancer Discov; 2019 Nov; 9(11):1606-1627. PubMed ID: 31350328
[TBL] [Abstract][Full Text] [Related]
4. Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional
Pore N; Wu S; Standifer N; Jure-Kunkel M; de Los Reyes M; Shrestha Y; Halpin R; Rothstein R; Mulgrew K; Blackmore S; Martin P; Meekin J; Griffin M; Bisha I; Proia TA; Miragaia RJ; Herbst R; Gupta A; Abdullah SE; Raja R; Frigault MM; Barrett JC; Dennis PA; Ascierto ML; Oberst MD
Cancer Discov; 2021 Nov; 11(11):2828-2845. PubMed ID: 34230008
[TBL] [Abstract][Full Text] [Related]
5. STK11/LKB1-Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/Type I Interferon/CD8
Li A; Wang Y; Yu Z; Tan Z; He L; Fu S; Shi M; Du W; Luo L; Li Z; Liu J; Zhou Y; Fang W; Yang Y; Zhang L; Hong S
J Thorac Oncol; 2023 Dec; 18(12):1714-1730. PubMed ID: 37495171
[TBL] [Abstract][Full Text] [Related]
6.
Sitthideatphaiboon P; Galan-Cobo A; Negrao MV; Qu X; Poteete A; Zhang F; Liu DD; Lewis WE; Kemp HN; Lewis J; Rinsurongkawong W; Giri U; Lee JJ; Zhang J; Roth JA; Swisher S; Heymach JV
Clin Cancer Res; 2021 Mar; 27(6):1720-1733. PubMed ID: 33323404
[TBL] [Abstract][Full Text] [Related]
7. STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.
Koyama S; Akbay EA; Li YY; Aref AR; Skoulidis F; Herter-Sprie GS; Buczkowski KA; Liu Y; Awad MM; Denning WL; Diao L; Wang J; Parra-Cuentas ER; Wistuba II; Soucheray M; Thai T; Asahina H; Kitajima S; Altabef A; Cavanaugh JD; Rhee K; Gao P; Zhang H; Fecci PE; Shimamura T; Hellmann MD; Heymach JV; Hodi FS; Freeman GJ; Barbie DA; Dranoff G; Hammerman PS; Wong KK
Cancer Res; 2016 Mar; 76(5):999-1008. PubMed ID: 26833127
[TBL] [Abstract][Full Text] [Related]
8. Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells.
Memmott RM; Gills JJ; Hollingshead M; Powers MC; Chen Z; Kemp B; Kozikowski A; Dennis PA
Cancer Res; 2008 Jan; 68(2):580-8. PubMed ID: 18199555
[TBL] [Abstract][Full Text] [Related]
9. Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy.
Mazzaschi G; Leonetti A; Minari R; Gnetti L; Quaini F; Tiseo M; Facchinetti F
Curr Treat Options Oncol; 2021 Sep; 22(11):96. PubMed ID: 34524570
[TBL] [Abstract][Full Text] [Related]
10. LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.
Facchinetti F; Bluthgen MV; Tergemina-Clain G; Faivre L; Pignon JP; Planchard D; Remon J; Soria JC; Lacroix L; Besse B
Lung Cancer; 2017 Oct; 112():62-68. PubMed ID: 29191602
[TBL] [Abstract][Full Text] [Related]
11. STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?
Di Federico A; De Giglio A; Parisi C; Gelsomino F
Eur J Cancer; 2021 Nov; 157():108-113. PubMed ID: 34500370
[TBL] [Abstract][Full Text] [Related]
12. LKB1 Loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K-AKT.
Kaufman JM; Amann JM; Park K; Arasada RR; Li H; Shyr Y; Carbone DP
J Thorac Oncol; 2014 Jun; 9(6):794-804. PubMed ID: 24828662
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of AMPK Leads to Attenuation of Antigen Presentation and Immune Evasion in Lung Adenocarcinoma.
Gao Y; Päivinen P; Tripathi S; Domènech-Moreno E; Wong IPL; Vaahtomeri K; Nagaraj AS; Talwelkar SS; Foretz M; Verschuren EW; Viollet B; Yan Y; Mäkelä TP
Clin Cancer Res; 2022 Jan; 28(1):227-237. PubMed ID: 34667030
[TBL] [Abstract][Full Text] [Related]
14. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP
J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
[TBL] [Abstract][Full Text] [Related]
16. Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy.
Ndembe G; Intini I; Moro M; Grasselli C; Panfili A; Panini N; Bleve A; Occhipinti M; Borzi C; Garassino MC; Marabese M; Canesi S; Scanziani E; Sozzi G; Broggini M; Ganzinelli M
J Exp Clin Cancer Res; 2024 Jan; 43(1):6. PubMed ID: 38163906
[TBL] [Abstract][Full Text] [Related]
17. PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer.
Long LL; Ma SC; Guo ZQ; Zhang YP; Fan Z; Liu LJ; Liu L; Han DD; Leng MX; Wang J; Guo XJ; Tan JL; Cai XT; Lin Y; Pan X; Wu DH; Bai X; Dong ZY
Cancer Res; 2023 Feb; 83(4):568-581. PubMed ID: 36512628
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer.
Rosellini P; Amintas S; Caumont C; Veillon R; Galland-Girodet S; Cuguillière A; Nguyen L; Domblides C; Gouverneur A; Merlio JP; Bezin J; Girodet PO
Eur J Cancer; 2022 Sep; 172():85-95. PubMed ID: 35759814
[TBL] [Abstract][Full Text] [Related]
19.
Pons-Tostivint E; Lugat A; Fontenau JF; Denis MG; Bennouna J
Cells; 2021 Nov; 10(11):. PubMed ID: 34831355
[TBL] [Abstract][Full Text] [Related]
20. Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden.
Salehi-Rad R; Li R; Tran LM; Lim RJ; Abascal J; Momcilovic M; Park SJ; Ong SL; Shabihkhani M; Huang ZL; Paul M; Shackelford DB; Krysan K; Liu B; Dubinett SM
Cancer Immunol Immunother; 2021 Aug; 70(8):2389-2400. PubMed ID: 33507343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
